Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Update

Acasti Pharma Inc. (NASDAQ:ACST) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 3,800 shares, a growth of 171.4% from the March 31st total of 1,400 shares. Based on an average daily trading volume, of 25,600 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the shares of the stock are short sold.

Acasti Pharma Stock Performance

ACST opened at $2.90 on Friday. The stock has a market cap of $27.26 million, a price-to-earnings ratio of -0.57 and a beta of 1.49. The stock’s 50 day moving average price is $3.32 and its 200-day moving average price is $2.74. Acasti Pharma has a one year low of $1.72 and a one year high of $3.84.

Acasti Pharma (NASDAQ:ACST) last released its earnings results on Monday, February 12th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. As a group, analysts predict that Acasti Pharma will post -1.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Craig Hallum assumed coverage on Acasti Pharma in a research note on Wednesday, February 7th. They set a “buy” rating and a $6.00 price objective on the stock.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.